Obesity Featured Articles

31. Psychedelic Clinical Trials: Methods And Mystique 6/17/2025

    The future of psychedelic medicine depends on applying strict scientific standards, using evidence-based approaches to manage the inherent challenges of studying these consciousness-altering compounds.

32. 5 Ways To Make Your Investigator Meetings Fun And Functional 6/17/2025

    Discover five ways CROs and sponsors can better engage and communicate with site staff for better relationships and better trials.

33. 25 Tips To Prepare A Clinical Site For FDA Inspection 6/17/2025

    During the last year I have interviewed six former FDA investigators and a regulatory expert who has been involved with more than 250 inspections. From all those interviews, I’ve culled the following list of takeaways that I hope you will find useful when preparing for any type of regulatory inspection.

34. Validating Generative AI: A Framework For Reliability And Compliance 6/16/2025

    With structured CSA-driven validation and expert guidance, organizations can harness generative AI’s advantages safely and effectively, ensuring accuracy, compliance, and operational excellence.

35. 2 Ways To Overcome The Challenge Of Developing Neurological Rare Diseases Drugs 6/16/2025

    GRIN Therapeutics CEO Bruce Leuchter, MD, explores how integrating new business models and technological advances will be crucial to developing new treatments for rare neurological disorders.

36. From Legacy To Lifeline: Advancing Rare Disease Care 6/13/2025

    Learn about inspiring figures who lived with rare diseases, get a look at today’s rare disease research, and see how we support patients around the world in this eBook.

37. What ASCO 2025 Means For The Future Of Oncology Trials 6/13/2025

    Review the ASCO 2025 Annual Meeting, highlighting oncology trials and the need for agile, globally capable CRO partners to navigate today’s evolving trial landscape.

38. Hidden Compliance Risks In Start-Up That Could Derail Your Clinical Trial 6/13/2025

    Kulkarni Law Firm Senior Attorney Edye T. Edens explores the risks embedded in clinical trial start-up activities, such as site activation, contract execution, delegation of responsibilities, and cross-border data flows.

39. We Need Regulatory Clarity—Not Complexity In Clinical Trial Technology 6/12/2025

    The current U.S. deregulatory momentum should not diminish compliance standards but instead serve as a call to streamline and modernize regulatory guidance.

40. HTA In Japan: The Glass Remains Half Full (For Now) 6/12/2025

    While Japan's current HTA system is seen as pro-innovation, potential reforms in 2026 could expand its scope, creating uncertainty for manufacturers in one of the world's largest markets.